Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (NASDAQ: PAVM) generates news across medical devices, diagnostics, and digital health, reflecting its role as a diversified, commercial-stage medical technology company. Its news flow often covers developments at the parent company level as well as at its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., which focus on cancer prevention diagnostics and digital cancer care.
Investors following PAVM news can expect updates on corporate actions, such as the announced 1-for-30 reverse stock split intended to help the company meet Nasdaq’s minimum bid price requirement and maintain its listing on the Nasdaq Capital Market. Company communications also highlight business updates, quarterly financial results, and information on balance sheet and capital structure decisions, often furnished through press releases and Form 8-K filings.
News related to Lucid Diagnostics, a subsidiary of PAVmed, frequently focuses on the commercialization and clinical performance of the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Recent announcements have described large real-world datasets on non-endoscopic esophageal precancer detection, Medicare coverage processes, and participation in medical and investor conferences.
Updates involving Veris Health typically center on the Veris Cancer Care Platform and its deployment in clinical settings. For example, PAVmed and Veris have reported the launch of the commercial phase of a long-term strategic partnership with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, focused on enhancing personalized cancer care for patients undergoing systemic cancer therapy.
This PAVM news page brings together these types of announcements, allowing readers to track financial disclosures, technology and platform milestones, regulatory and reimbursement developments, strategic partnerships, and corporate governance actions over time.
Summary not available.
Summary not available.
Summary not available.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has appointed Gary Manning as the President of its majority-owned subsidiary, Veris Health. Manning brings over 30 years of digital health and medical technology experience, which includes expertise in developing innovative solutions for patient care. His role will focus on driving the commercialization of the Veris Cancer Care Platform™ and guiding product development and regulatory milestones for an implantable cardiac monitor. Chairman and CEO Lishan Aklog expressed confidence in Manning's ability to enhance Veris’s strategic direction. The Veris Cancer Care Platform enables remote monitoring of cancer patients, integrating Bluetooth-enabled devices to transmit health data. This appointment is anticipated to strengthen Veris's market position in personalized cancer care.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) presented a meta-analysis on Remote Patient Monitoring (RPM) at the HIMSS23 Global Health Conference on April 19, 2023. This analysis, titled "RPM for Oncology: Bringing the Hospital Home to Improve Lives," highlights RPM's potential to enhance quality of care, reduce healthcare costs, and improve patient experiences. The meta-analysis reviewed nearly two decades of oncology research from over ten countries, emphasizing the integration of RPM with patient-reported outcomes (ePROs) for personalized cancer care. PAVmed's digital health subsidiary, Veris Health, showcased its Veris Cancer Care Platform™ during the session, which enables remote monitoring and real-time data transmission to improve patient management.
Lucid Diagnostics announced that Noridian Healthcare Solutions published a Future Effective Local Coverage Determination (LCD) DL39262, effective May 28, 2023. This LCD relates to molecular testing for esophageal precancer and cancer in Medicare beneficiaries. Lucid's EsoGuard Esophageal DNA Test is the only test in its category and aims to serve as a screening tool for at-risk patients. The LCD aligns with criteria from the Palmetto GBA MAC's MolDX Program. Lucid plans to secure clinical utility data and submit EsoGuard for Technical Assessment under these LCDs later this year, potentially expanding its testing access.
The company's CEO, Lishan Aklog, emphasized the milestone for increasing EsoGuard's accessibility to Medicare beneficiaries.
Lucid Diagnostics Inc. (NASDAQ: LUCD), a cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM, PAVMZ), announced its participation in the 22nd Annual Needham Healthcare Conference. Executives Dr. Lishan Aklog and Dennis McGrath will present on April 20, 2023, at 11:00 AM ET. Lucid focuses on patients with gastroesophageal reflux disease (GERD), a condition that increases the risk of esophageal precancer and cancer. Their flagship product, the EsoGuard® Esophageal DNA Test, is a non-invasive tool designed for early cancer detection in at-risk patients. For those interested in meeting with management during the conference, inquiries can be directed to Needham representatives. For more details, visit luciddx.com.
Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention diagnostics company and a subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that its leadership team, including Dr. Lishan Aklog and Dennis McGrath, will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023, at 11:00 AM ET.
Lucid's focus is on patients with gastroesophageal reflux disease (GERD), at risk of esophageal cancer. Their EsoGuard® Esophageal DNA Test, a non-invasive diagnostic tool, is designed for early detection of esophageal precancer. This test is significant as it is the first commercially available screening tool targeting at-risk GERD patients.
For more details, visit luciddx.com or pavmed.com.
Lucid Diagnostics Inc. announced the publication of a Future Effective Local Coverage Determination (LCD) by the MolDX Program, effective May 14, 2023. This foundational LCD establishes coverage criteria for molecular testing of esophageal precancer and cancer for Medicare beneficiaries. Lucid plans to submit its EsoGuard Esophageal DNA Test for Technical Assessment under this LCD by the end of 2023, aiming to provide non-invasive testing alternatives to traditional endoscopy. The LCD incorporates feedback from stakeholders and aligns with the American College of Gastroenterology's guidelines, emphasizing early detection to prevent esophageal cancer deaths.
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) announced a business update and financial results for the year ended December 31, 2022. The company's restructuring plan has extended its cash runway, securing $24.6 million financing for Lucid Diagnostics, which is expected to last into 2024. Veris Health launched its Cancer Care Platform, enhancing patient monitoring. EsoGuard testing volume is growing, with recent agreements increasing access to up to 60 million consumers through MultiPlan. However, 2022 revenues were just $0.4 million, with a net loss of $89.2 million.